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The replication of human immunodeficiency type-1 (HIV-1) is restricted in macaque cells, in part due to host factors that provide intrinsic
immunity after entry. Here we show that a rhesus macaque epithelial cell line engineered to express human CD4, sMAGI cells, has at least two
post-entry restrictions to HIV-1 replication: one that is dependent on a previously described post-entry restriction factor of macaque cells,
TRIM5α, and another that is primarily TRIM5α-independent. The TRIM5α restriction, which was observed with particles that had an HIV-1 core
pseudotyped with VSV-G envelope, is saturable and can be completely abrogated by introducing TRIM5α-specific siRNA into the cells. A similar
TRIM5α-dependent restriction was observed when sMAGI cells expressing human CCR5 were infected with an R5-HIV-1. In contrast, even
when viruses enter sMAGI cells using CD4 and an endogenous rhesus coreceptor at levels sufficient to saturate TRIM5α, they do not productively
infect the sMAGI cells. Nor does treatment of sMAGI cells with TRIM5α-specific siRNA relieve this post-entry restriction; this was true whether
the HIV-1 core was pseudotyped with SIV envelope or an R5-HIV-1 envelope. Together these data suggest that there is an alternate restriction to
replication, here called Lv3, that is encountered by viruses that enter via interaction with CD4 and an endogenous rhesus coreceptor. Thus, these
findings suggest that post-entry events are dependent upon the mechanism by which HIV-1 enters the cell.
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The ability of human immunodeficiency virus type 1 (HIV-1)
to replicate in a particular cell is determined by multiple
requisite interactions between the virus and that target cell. The
first of these is binding of the envelope surface unit to the
receptor CD4 and a coreceptor, typically CCR5, which initiates
fusion of the viral and cellular membranes (reviewed in Berger
et al., 1999). Once inside the cell, HIV-1 must then overcome
several countermeasures within the cell that provide anti-
retroviral intrinsic immunity. These factors, typified by the
recently discovered TRIM5α and APOBEC3G proteins
(reviewed in Zheng and Peterlin, 2005) are most often cell-
type-specific, and viruses that are unable to counter these
intrinsic immunity factors in a cell are blocked in their
replication. Thus, multiple virus–host interactions, both at the⁎ Corresponding author.
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doi:10.1016/j.virol.2007.02.002plasma membrane and within the cell, contribute to the host cell
specificity of HIV-1.
Previously, this lab described a rhesus macaque epithelial
cell line expressing human CD4 (sMAGI) that can be
productively infected by SIV (Chackerian et al., 1995), but
not by HIV-1 (Chackerian et al., 1997). sMAGI cells do not
express any of the major HIV-1 or SIV coreceptors (CCR5,
CXCR4, GPR15 or CXCR6), suggesting that they express a
novel coreceptor that has yet to be identified (Pohlmann et al.,
2004; Pineda and Overbaugh, unpublished data). Despite the
absence of a known HIV-1/SIV coreceptor, sMAGI cells permit
entry of some HIV-1 strains, as evidenced by the accumulation
of cytoplasmic, late reverse transcription intermediates (Chack-
erian et al., 1997). This post-entry restriction encountered by
some HIV-1, typified by the R5 viral clone HIV-1 SF162, was
rescued by complementing the HIV-1 envelope with SIV genes
as a SHIV chimera. Productive infection was also observed for
R5-HIV-1 in sMAGI cells that were engineered to express
human CCR5 (sMAGI-CCR5) (Chackerian et al., 1997). Thus,
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well as by the nature of the envelope/coreceptor interactions.
Subsequently, two post-entry restrictions that bear some
similarities to the HIV-1 restriction observed in sMAGI cells
have been described in other primate cells: Lv1 (Cowan et al.,
2002) and Lv2 (Marchant et al., 2005; McKnight et al., 2001;
Schmitz et al., 2004). While the molecular mechanism
responsible for mediating the Lv2 restriction is unclear, the
cellular factor responsible for the Lv1 restriction has been
identified as TRIM5α (Stremlau et al., 2004). TRIM5α
restriction occurs during uncoating and reverse transcription
(Bieniasz, 2003; Cowan et al., 2002) and is thought to be the
result of accelerated uncoating of capsid in the viral particle
(Stremlau et al., 2006). The TRIM5α restriction is saturable:
infecting target cells with a viral inoculum above a threshold
dose results in breakthrough infection of the target cells. The
Lv2 restriction is also dependent on capsid, but it is
distinguished from the TRIM5α restriction in that the restriction
is influenced by the viral envelope protein: some viral
envelopes target HIV-1 to an Lv2-restricted compartment,
while other viral envelopes shuttle HIV-1 to a compartment in
which Lv2 is absent or less potent (Marchant et al., 2005).
Here, we examined the role of TRIM5α in the post-entry
restriction to HIV-1 infection in sMAGI cells. We showed that
in sMAGI cells engineered to express human CCR5, TRIM5α
is an intrinsic early post-entry inhibitor to R5-HIV-1. TRIM5α
also caused a restriction to HIV-1 particles pseudotyped with the
glycoprotein of vesicular stomatitis virus (VSV-G) in sMAGI
cells. However, the post-entry restriction to R5-HIV-1 in
sMAGI cells lacking human CCR5 was not dependent on
TRIM5α. In sMAGI cells, HIV-1 cores pseudotyped with either
HIV-1 or SIV envelope remained restricted even at doses that
saturate TRIM5α. These data suggest that within this single cell
type, there are two mechanisms of restriction to R5-HIV-1.
Results
The restriction to HIV-1 SF162 infection in sMAGI cells is not
overcome with increasing virus dose or by reducing TRIM5α
levels
The post-entry restriction to HIV-1 SF162 and other variants
that was previously described in sMAGI cells was observed
when testing viruses at a fixed dose that was presumably less
than one infectious virus particle per cell (0.25 TCID50 based onFig. 1. Infection of sMAGI cells and human MAGI-CCR5 across a range o
virus doses. The number of blue, β-galactosidase-positive cells was determined
using microscopy to count blue cell foci, which has an upper range or reliable
quantification at ∼1000 blue cells. The X-axis represents increasing infectious
dose of virus as defined by Gagp24 (or Gagp27 for SIV) concentration. Error
bars represent standard deviation of three replicate infections. The average
number of blue cells detected in mock-infected cells was subtracted from each
data point. Hollow symbols represent the number of infected rhesus sMAG
cells; black solid symbols represent the number of infected humanMAGI-CCR5
cells: (A) infection with HIV-1/SF162; (B) infection with HIV-1/VSV-G; (C)
infection with SIV/VSV-G; (D) infections with HIV-1/VSV-G (square symbols
and SIV/VSV-G (circle symbols) in the presence of HIV-1 VLP with a VSV-G
envelope (left panel) or HIV-1 VLP lacking envelope (right panel).f
I
)infection of permissive human cells per sMAGI cell: Chack-
erian et al., 1997). To test whether the restriction to HIV-1
SF162 in rhesus sMAGI cells could be overcome by saturation,
Fig. 2. Effect of reducing TRIM5αmRNA levels by small interfering RNA. The
results are presented as the percentage of GFP-positive cells, as determined by
flow cytometry. The siRNA tested in the cells is indicated below the bar graph.
Legend shows key to the cell/virus combinations tested with each siRNA
condition. Rhesus sMAGI cells and human MAGI-CCR5 were transfected with
the indicated siRNA at a final concentration of 120 nM (see Materials and
methods). At 2 days after siRNA transfection, cells were infected with HIV-1/
SF162 or HIV-1/VSV-G at a MOI of ∼1.0, based on titers in permissive human
MAGI-CCR5 cells. Error bars represent standard deviation of three replicate
infections.
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particles pseudotyped with HIV-1 SF162 envelope protein
(HIV-1/SF162) (Fig. 1A). Little or no productive infection
above background variation (typically this variation is 5–10
blue cells depending on the experiment) was observed in rhesus
cells infected with HIV-1/SF162 over the greater than four-log
range of viral doses tested (Fig. 1A). In contrast, the number of
β-galactosidase-positive cells increased in direct relation with
the increasing doses of HIV-1/SF162 in a permissive human cell
line used as a control-human HeLa cells engineered to express
human CD4 and human CCR5, MAGI-CCR5 cells (Chackerian
et al., 1997)-reaching the upper limit of reliable quantification at
an input virus level of approximately 1000 ng p24 Gag
(corresponding to an MOI of ∼0.1; Fig. 1A).
The TRIM5α restriction has most extensively been studied
with HIV-1 particles pseudotyped with the glycoprotein of the
vesicular stomatitis virus (HIV-1/VSV-G); it has also been
specifically demonstrated for wild type HIV-1 in some cells
(Munk et al., 2002; Stremlau et al., 2004). Given the focus on
HIV-1/VSV-G infection in several previous studies, we wanted
to specifically examine whether HIV-1/VSV-G was restricted in
sMAGI cells and whether the restriction was similar to that of
HIV-1/SF162. We observed a restriction to HIV/VSV-G in
sMAGI cells at low doses of input virus, but unlike the
restriction of HIV-1/SF162, this restriction was abrogated by
increasing the dose of virus (Fig. 1B). As expected, the repli-
cation of SIV/VSV-G, a SIV core pseudotyped with VSV-G
envelope, was not restricted in the sMAGI cells; the infectivity
of SIV/VSV-G was similar in rhesus sMAGI and humanMAGI-
CCR5 cells across all virus doses tested (Fig. 1C). The
restriction to HIV-1/VSV-G could be abrogated by adding
high doses of virus-like particles pseudotyped with VSV-G
envelope, but it was not affected by the addition of virus-like
particles lacking envelope (Fig. 1D). Together, these data
suggest there is a saturable restriction to HIV-1/VSV-G, but not
to SIV/VSV-G, in sMAGI cells, suggesting that this restriction
may be due to TRIM5α. In contrast, there is a restriction to HIV-
1/SF162 that cannot be saturated by increasing the virus dose.
To more directly examine whether there was a role for
TRIM5α in the restriction to HIV-1SF162 in sMAGI cells,
TRIM5α mRNA concentrations were reduced by transfection
with short interfering RNA (siRNA3) that targets rhesus
TRIM5α (Stremlau et al., 2004). To increase the upper limit
of quantification of infected cells, rhesus sMAGI cells were
infected with virus carrying an HIV-1 proviral genome
encoding an enhanced green fluorescent protein (eGFP;
Yamashita and Emerman, 2004), and flow cytometry was
used to detect eGFP-positive infected cells. As a positive
control for this experiment, we showed that TRIM5α-specific
siRNA pre-treatment of sMAGI cells restored the infectivity of
the HIV-1/VSV-G control virus to the same levels as permissive
human cells (Fig. 2; compare light and dark gray shaded bars in
siRNA3). TRIM5α-specific siRNA pre-treatment of sMAGI
cells also resulted in an increase in the percentage of eGFP-
positive sMAGI cells upon exposure to HIV-1/SF162 (from
0.08% to 0.56%, compare black bars in no siRNA versus
siRNA3 in Fig. 2). However, there remained a ∼32-folddifference in infectivity of HIV-1/SF162 in rhesus versus
permissive human cells (0.56% vs. 18.38%; compare white and
black bars in siRNA3), even when TRIM5α levels were
reduced to levels that completely abrogated the restriction to
HIV-1/VSV-G in the rhesus cells. The differential ability of
TRIM5α siRNA to abrogate the restriction of HIV-1/SF162 and
HIV-1/VSV-G was also observed at other doses of virus (data
not shown). These findings were specific to the siRNA directed
to TRIM5α and were not seen with a control siRNA (Fig. 2).
The presence or absence of TRIM5α-specific siRNA had no
discernable effect on the percentage of HIV-1/VSV-G or HIV-1/
SF162 infected human cells, consistent with previous reports
suggesting that human TRIM5α does not appreciably restrict
HIV-1 (Stremlau et al., 2004; Fig. 2). Together, these
experiments indicate that under the same conditions where
HIV-1/VSV-G TRIM5α-restriction is completely abrogated,
there remains a significant restriction to HIV-1/SF162 in
sMAGI cells.
Infection of sMAGI cells expressing human CCR5
Our previous studies suggested that HIV-1 SF162 restriction
was dependent on the route of viral entry because rhesus sMAGI
cells that express human CCR5 (sMAGI-CCR5) were infectable
by R5-HIV-1 (Chackerian et al., 1997). Here, we tested whether
HIV-1/SF162 had a saturable, TRIM5α-dependent phenotype in
these cells. In sMAGI-CCR5 cells, HIV-1/SF162 showed
evidence for a restriction at lower doses, but not at higher
doses; as expected this abrogation of restriction was not seen
with HIV-1/SF162 tested in parallel on sMAGI cells (Fig 3A). In
contrast, HIV-1/VSV-G infectivity was similar across all doses
in sMAGI-CCR5 and sMAGI cells, approaching the infectivity
Fig. 4. Quantification of HIV-1 SF162 proviral DNA in sMAGI and sMAGI-
CCR5. Cells were infected with viruses at the indicated concentration. To
minimize signal due to any remaining contaminating DNA in the virus, the
background HIV-1 DNA copies observed in AZT/3TC treated cultures, infected
at the indicated virus dose, have been subtracted. Error bars represent standard
deviation in the HIV-1 pol DNA copy number of two replicate infections. The
dashed line highlights the number of proviral DNA per twenty thousand cells in
sMAGI-CCR5 cells infected with HIV-1 SF162 at the lowest viral dose at which
productively infected sMAGI-CCR5 cells were detected by counting GFP-
positive cells (not shown, but see Fig. 3). This level of proviral DNA thus
represents a threshold level that corresponds to productive infection.
Fig. 3. Viral infectivity of sMAGI-CCR5 vs. sMAGI cells. The percentage of
GFP-positive cells versus virus dose was determined by flow cytometry. Error
bars represent standard deviation of three replicate infections. Open triangles
represent the number of infected rhesus sMAGI-CCR5 cells, filled triangles
represent the number of infected rhesus sMAGI cells, and black squares
represent the number of infected human MAGI-CCR5 cells: (A) infection with
HIV-1/SF162; (B) infection with HIV-1/VSV-G. The infections in the two
panels were performed in parallel.
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(Fig. 3B). TRIM5α siRNA abrogated the restriction of HIV-1/
SF162 in sMAGI-CCR5 cells, as evidence by a ∼10-fold
increase in positive cells at input virus concentrations of 1–10 ng
Gag p24 (data not shown). These data suggest that infection of
rhesus sMAGI-CCR5 cells with an R5-HIV-1 results in the same
saturable, TRIM5α-dependent restriction as infection with HIV-
1/VSV-G.
TRIM5α-mediated restriction occurs before reverse tran-
scription, as evidenced by a lack of HIV-1 DNA reverse
transcription intermediates in restricted cells exposed to non-
saturating levels of HIV-1 (Cowan et al., 2002). As the
restriction to TRIM5α is saturated with increasing amounts of
virus, reverse transcriptase intermediates accumulate and
productive infection ensues. To further examine whether the
restriction to HIV-1/SF162 in sMAGI cells is independent of
TRIM5α, we examined whether reverse transcriptase inter-
mediates accumulate in sMAGI cells exposed to HIV-1/SF162
at levels comparable to those seen during permissive infection.
The infection was performed across a range of doses, starting
at Gag p24 concentration of ∼0.1 ng (corresponding to an
MOI of ∼0.016 based on infection of permissive humancells). We chose this dose because it was around the lowest
dose where HIV-1/SF162 infection can first be detected in
permissive sMAGI-CCR5 cells (e.g. Fig. 3 and data not
shown), which served as a positive control for this experiment.
At this lowest virus dose, we detected 25 HIV-1 proviral
copies per 20,000 sMAGI-CCR5 cells plated for infection
(Fig. 4). Therefore, ≥25 copies per 20,000 sMAGI-CCR5
cells infected represents the level of proviral copies that
correspond to the threshold where productive infection can be
detected in these cells. Beginning at a Gag p24 concentration
of ∼2 ng/ml for HIV-1/SF162, the copy number of reverse
transcription intermediates exceeded this saturation threshold
number (25 copies/20,000 cells infected; denoted by a hatched
line in Fig. 4) in the non-permissive rhesus sMAGI cells.
It is worth noting that the HIV-1/SF162 infection of rhesus
cells at all doses tested was reduced an average of 100-fold
compared to the parallel HIV-1/SF162 infection of sMAGI-
CCR5 cells. This reduction in proviral copy number in rhesus
cells suggests that compared to HIV-1 SF162 infection of
sMAGI-CCR5 cells, HIV-1/SF162 may have reduced entry
efficiency in rhesus sMAGI cells expressing only the
endogenous rhesus coreceptor. To test this, we performed a
fusion experiment comparing the efficiency of fusion of the
HIV-1/SF162 envelope in the two cell lines. In this assay,
envelope-positive syncytia indicate that the viral envelope of
interest has fused with the target cells – a prerequisite for viral
entry. We observed a ∼5-fold increase in HIV-1/SF162-positive
syncytia in sMAGI-CCR5 cells compared to sMAGI cells and a
similar increase when we compared human cells expressing
CCR5 (MAGI-CCR5 cells) and sMAGI cells. As expected, a
control CXCR4-using envelope, HIV-1 SF33, caused a similar
level of syncytia whether or not CCR5 was expressed in the
human cells (Fig. 5A). These data support the suggestion that
Fig. 5. Comparison of the efficiency of fusion of envelope with sMAGI cells
compared to cells expressing CCR5. Envelope-positive syncytia scored using an
immunofluorescence fusion assay are shown. The viruses tested are indicated at
the bottom of each chart and the coding for the cell lines tested is indicated at the
very bottom of the figure. (A) Fusion of HIV-1 SF162 and a CXCR4 viral
envelope HIV-1 SF33 with sMAGI-CCR5, sMAGI, MAGI-CCR5 and MAGI
cells. (B) Fusion of SIVMneCL8 envelope with sMAGI, MAGI-CCR5 and
MAGI cells. The HIV-1 envelopes shown in panel Awere included as controls.
Arrows indicate results where the values were above 0, but below 10 syncytia.
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sMAGI cells expressing only the endogenous rhesus coreceptor
compared to cells expressing CCR5.
Despite the apparent reduction in fusion and entry efficiency
of HIV-1/SF162 in sMAGI versus sMAGI-CCR5 cells, the
number of proviral copies detected in sMAGI cells infected with
HIV-1 SF162 increased with increasing virus dose, reaching
nearly 1000 proviral copies per 20,000 cells infected at the
highest dose of virus tested (Fig. 4). Thus, HIV-1 SF162
infection of sMAGI cells resulted in levels of reverse
transcription intermediates that are indicative of productive
infection of HIV-1 SF162 in sMAGI-CCR5 cells (Fig. 4); in
sMAGI cells, there remains a block to HIV-1/SF162 at a stage
after reverse transcription even at the highest virus doses (Figs.
1 and 3).
HIV-1 infection of sMAGI cells is not limited by inefficient
entry
The detection of reverse transcriptase intermediates suggest
that the inability of HIV-1/SF162 to saturate TRIM5α in the
rhesus sMAGI cells is not likely to be due simply to limited
entry of the virus by the endogenous coreceptor. As anotherapproach to rule out this possibility, we infected rhesus sMAGI
cells with HIV-1 particles pseudotyped with an envelope protein
from SIV (HIV-1/SIV), because the infectivity of SIV is
comparable between human MAGI-CCR5 cells and rhesus
sMAGI cells (Chackerian et al., 1995, 1997). Moreover, we
observed that the SIVenvelope induced a ∼10-fold higher level
of envelope-positive syncytia in sMAGI cells compared to
human cells expressing CCR5, further demonstrating that there
are no restrictions that would be expected to limit fusion and
entry of a HIV-1 particle pseudotyped with an SIV envelope in
sMAGI cells (Fig. 5B). HIV-1/SIV infection of rhesus cells
could not be detected above background even at the highest
dose tested, which corresponded to 10 infectious particles
(based on infection of permissive human cells) per sMAGI cell;
in the same experiment, HIV-1/VSV-G infection was detected at
these high virus doses (Fig. 6A). Parallel infection of human
cells with HIV-1/SIV, as well as HIV-1/VSV-G, demonstrated
that the viruses were equally infectious in human cells (Fig. 6B).
Thus, HIV-1 pseudotyped with an SIV envelope protein, which
permits efficient entry into sMAGI cells, is unable to saturate
the post-entry restriction factor present in sMAGI cells.
To determine if TRIM5α restricts HIV-1/SIV, we infected
rhesus sMAGI cells with HIV-1/SIV that had been treated with
TRIM5α-specific siRNA (Fig. 6C). TRIM5α-specific siRNA3
pre-treatment of rhesus cells rescued the infection of HIV-1/SIV
from ∼0.7% infected rhesus cells in the absence of TRIM5α-
specific siRNA to ∼4.4% infected rhesus cells in the presence
of TRIM5α-specific siRNA, siRNA3 (Fig. 6C). However, this
is far short of the almost 60% infected cells observed in parallel
HIV-1/SIV infections of human cells at this dose of virus.
Consistent with the results of the experiment shown in Fig. 2, in
this experiment, HIV-1/VSV-G infections of rhesus cells were
rescued to levels near those observed in human cells upon pre-
treatment with siRNA3. Thus, the restriction to HIV-1/SIV in
rhesus sMAGI cells, like the restriction to HIV-1/SF162, is only
partially relieved by reduction of TRIM5α, even under
conditions where the restriction to HIV-1/VSV-G is abrogated.
Discussion
A rhesus cell line that expresses human CD4 (sMAGI;
Chackerian et al., 1995, 1997) and an as yet unidentified
endogenous coreceptor, restricts HIV-1 by two distinct
mechanisms: one that is dependent on TRIM5α and another
that is primarily independent of TRIM5α. sMAGI cells have a
TRIM5α-mediated, saturable restriction to infection by HIV-1
pseudotyped with VSV-G. Additionally, HIV-1 encountered the
same TRIM5α-dependent restriction in sMAGI cells that have
been engineered to express human CCR5 (sMAGI-CCR5). In
contrast, HIV-1 that entered sMAGI cells using an endogenous
rhesus coreceptor were restricted after reverse transcription, but
by a mechanism that was largely independent of TRIM5α.
There was a very modest positive effect of reducing TRIM5α
levels on HIV-1/SF162 infection of sMAGI cells, but even
under conditions where the TRIM5α restriction of HIV-1/VSV-
G was completely abrogated, HIV-1/SF162 infectivity was
∼32-fold lower relative to permissive cells. This suggests that,
Fig. 6. Infection of rhesus sMAGI and human MAGI-CCR5 cells with HIV-1/
SIV. The percentage of GFP-positive cells versus virus dose was determined by
flow cytometry. Shaded regions represent the percentage of GFP-positive cells
detected in mock (no virus)-treated cells. Error bars represent standard deviation
of three replicate infections. The symbols used for various cell/virus
combinations tested are shown within each panel. (A) Infection of rhesus
sMAGI cells with increasing dose of HIV-1/SIV and HIV-1/VSV-G. (B)
Infection of MAGI-CCR5 cells with increasing dose of HIV-1/SIV and HIV-1/
VSV-G. (C) Effects of TRIM5α-specific siRNA treatment of sMAGI and
MAGI-CCR5 cells on infection of HIV-1/SIV. Transfection of siRNA was
performed as in Fig. 2. In this experiment, we maintained the control HIV-1/
VSV-G MOI at 1.0 but increased the MOI of HIV-1/SIV (to 2.0) to increase the
likelihood that we might observe a substantial change in the percentage of HIV-
1/SIV infected rhesus cells upon siRNA-mediated reduction of TRIM5α
mRNA.
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provides intrinsic immunity against HIV-1 infection in rhesus
cells.
Infection of sMAGI-CCR5 cells with HIV-1/SF162 led to
saturation of endogenous rhesus TRIM5α and resulted in
productive infection. However, sMAGI cells lacking CCR5
that were infected with HIV-1/SF162 in parallel remained
uninfected over the wide range of doses tested. Analyses of
reverse transcription intermediates, which provide a surrogate
measure of the extent of viral entry (Zack et al., 1990),
suggested that the inability of HIV-1/SF162 to saturate
TRIM5α is not simply due to limited entry at higher doses.
HIV-1/SF162 reverse transcriptase intermediates reached
levels in sMAGI cells that were well above the level at
which TRIM5α was saturated in sMAGI-CCR5 cells. The
inability to abrogate the restriction of HIV-1/SF162 in sMAGI
cells even at virus levels where there is clear evidence for
reverse transcriptase intermediates, together with the finding
that siRNA knock down of TRIM5α does not render the cells
permissive to HIV-1/SF162 infection, strongly suggest that the
major post-entry restriction encountered by HIV-1/SF162 in
sMAGI cells is distinct from TRIM5α. Here we call the
restriction Lv3 for Lentiviral restriction factor 3.
We further examined the potential role of limited entry in
the observed phenotype of HIV-1/SF162 by examining
infection of particles that had an HIV-1 core, but a different
envelope. We chose the SIV envelope because sMAGI cells
are highly permissive to infection by SIV (Chackerian et al.,
1995) and there is efficient fusion of SIV envelope with
sMAGI cells even compared to cells expressing CCR5,
suggesting that entry is not limited. HIV-1 pseudotyped with
an SIV envelope was also restricted in sMAGI cells over a
wide range of doses tested. This suggests that HIV-1 cores
that enter via an endogenous coreceptor for SIV also
encounter the Lv3 restriction. We do not know if the
coreceptor used by HIV-1 SF162 and SIV are the same, but
the similarity of the restriction of HIV-1 cores bearing these
envelopes suggests that this could be the case. It is possible
that HIV-1 infection of sMAGI cells that use CD4 and the
endogenous sMAGI coreceptor deposits HIV-1 cores into a
different cellular context than HIV-1/VSV-G infection of
sMAGI cells in which entry is mediated by endocytosis. In
this model, HIV-1 cores that enter sMAGI cells using CD4
and the endogenous coreceptor are shuttled down a pathway
in which they do not encounter TRIM5α, but do encounter
Lv3. In contrast, HIV-1 cores that enter by VSV-G-mediated
endocytosis bypass the Lv3 restriction, but encounter the
TRIM5α-dependent restriction.
Previous studies have also provided evidence that the
mechanism of HIV-1 entry influences the intracellular
compartment into which HIV-1 is deposited and, therefore,
the success of post-entry stages of HIV-1 replication.
Bukrinskaya et al. (1998) demonstrated that disruption of
the actin cytoskeleton resulted in an early post-entry restriction
of HIV-1 that entered cells using CD4 and CXCR4 via wild
type HIV-1 envelope-mediated entry; however, the require-
ment for an intact actin cytoskeleton was bypassed by HIV-1
316 M.J. Pineda et al. / Virology 363 (2007) 310–318that enter cells by endocytosis via VSV-G-mediated entry.
Schmidtmayerova et al. (1998) showed that T-lymphotropic
HIV-1 entered macrophages in a CD4/CXCR4-dependent
manner, but were restricted prior to nuclear import, whereas
HIV-1 that entered via CD4/CCR5 were not restricted.
Because CCR5 and CXCR4 have been shown to localize to
different plasma membrane microdomains (Popik et al., 2002),
differences in coreceptor localization may account for the role
that envelope-coreceptor interactions play in determining the
location, and therefore, the success of post-entry stages of
HIV-1 replication.
Lv3 also shares similarities to the intrinsic immunity factor
Lv2. Lv2 was first described as a post-entry restriction to
HIV-2 infection in macrophages and some human cell lines
(e.g. GHOST cells and HeLa-CD4 cells) that is distinct from
Lv1/TRIM5α restriction of HIV-1 (McKnight et al., 2001;
Schmitz et al., 2004). Recently, Marchant et al. (2005)
demonstrated that altering the route of entry determined
whether HIV-2 encountered Lv2 in restrictive cells. Moreover,
it appears that some HIV-1 strains also encounter Lv2
(Marchant et al., 2005). Schmitz et al. (2004) demonstrated
that HIV-2 restricted envelopes direct restricted HIV-2 cores
to a non-productive pathway; escape from this non-productive
pathway is possible if the restricted envelope is complemen-
ted with a non-restricted CA protein. The infection of sMAGI
cells that results in the Lv3 restriction can be rescued by
complementing HIV-1 SF162 Env-mediated infection with an
unrestricted SIV gag–pol (Chackerian et al., 1997). Thus, a
salient characteristic shared by Lv2 and Lv3 is the ability of
5′ viral sequences to rescue the post-entry restriction. Another
common feature is that Lv2 was bypassed when HIV particles
were pseudotyped with VSV-G (Schmitz et al., 2004), as was
Lv3 for HIV-1. There are differences, however, between Lv3
and Lv2. Infection of Lv2-restrictive HeLa-CD4 cells is leaky,
as low-level productive infection can be detected; in contrast,
Lv3-restrictive sMAGI cells cannot be productively infected
even at high viral doses. Unlike Lv3, Lv2 is apparently not
coreceptor-dependent, as expression of alternate coreceptors
in cells does not modulate the Lv2 phenotype (Schmitz et al.,
2004). Lv2 and Lv3 are also distinct in being present in
different species, and it remains to be seen whether Lv3 is
common in other species or even other cells from rhesus
monkeys. The relationship of the Lv2 restriction and the Lv3
restrictions remains to be determined, but it is possible they
will share some overlapping mechanisms.
The ability of HIV-1 to engage the necessary cellular
components as it navigates from the inner leaf of the plasma
membrane to the nucleus is, in part, determined by the
mechanism of entry. The studies described here, suggest that
within a single cell, multiple potential pathways exist, some of
which may be non-productive for infection. In addition to
TRIM5α, a restriction we have termed Lv3 results in a post-
entry restriction to HIV-1 infection in a rhesus epithelial cell
line. Lv3 is distinguished by its dependence on the entry
pathway of the virus, by the fact that the restriction occurs at
least in part after reverse transcription and by the fact that the
restriction is not saturated at high doses of virus or by reductionof TRIM5α levels. Further characterization of this early post-
entry restriction may provide novel therapeutic targets to
combat HIV infection.
Materials and methods
Cell lines
The sMAGI cell line (Chackerian et al., 1997) was derived
from a rhesus macaque epithelial cell line (CMMT) and was
engineered to express human CD4. The sMAGI derivative cell
line sMAGI-CCR5 was engineered to express human CCR5.
sMAGI and sMAGI-CCR5 cells were cultured in DMEM
complete (Dulbecco's modified Eagle's medium supplemented
with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin, 0.25 mg/ml amphotericin
B) supplemented with 50 U/ml hygromycin and 50 μg/ml G418
(and 6 μg puromycin/ml derivatives). The MAGI-CCR5
(Chackerian et al., 1997) cell line was cultured in DMEM
complete supplemented with 100 μg/ml hygromycin, 50 μg/ml
G418 and 1 μg/ml puromycin.
Construction of envelope expression plasmids
Amplicons encoding full-length HIV-1 envelopes were
generated by polymerase chain reaction (PCR) amplification
of the 3′ hemi-genome of HIV-1 SF162 (Cheng-Mayer et al.,
1990) and HIV-1 SF33 (York-Higgins et al., 1990) using the
second round primers vpr11 and nef30 described by Long et al.
(2002). HIV-1 envelope PCR was performed with Native Pfu
DNA Polymerase from Stratagene (La Jolla, CA) according to
the manufacturer's instructions. The reaction was performed
using AmpliWax PCR Gem 50 wax beads, using the hot start
method (Applied Biosystems, Foster City, CA). The thermo-
cycling conditions were as follows: 94 °C for 2 min; 25 cycles
of 94 °C for 45 s, 55 °C for 45 s, 72 °C for 4.5 min; and a final
incubation at 72 °C for 10 min. HIV-1 envelope (env) PCR
amplicons were digested with NotI and MluI and cloned into
NotI and MluI restriction enzyme-digested pCI-Neo (Promega,
Madison, WI) to generate pCI-Neo-HIV-1SF162env. The
sequence of the clone used was verified by nucleotide
sequencing of both strands.
Full-length SIVMneCL8 (M32741) envelope (referred to as
SIV env for simplicity) was generated by PCR amplification of
full-length genome of SIVMneCL8 using SIVenv35 (5′-AAA
CAA GAA TTC ATG GGA TCT CTT GGG AAT CAG
(6060–6092, position relative to SIVMneCL8)) and SIVenv36
(5′-TTG TAT TGC GGC CGC TCA CAA GAG AGT AAG
CTC GAG (8697–8732)). SIV envelope PCR was performed
with Native Pfu DNA Polymerase from Stratagene (La Jolla,
CA) according to the manufacturer's instructions. The reaction
was performed using AmpliWax PCR Gem 50 wax beads,
using the hot start method (Applied Biosystems, Foster City,
CA). The thermocycling conditions were as follows: 94 °C for
2 min; 25 cycles at 94 °C for 45 s, 63 °C for 45 s, 72 °C for
4 min; and a final incubation at 72 °C for 10 min. The full-
length SIVCL8env PCR amplicon was digested with NotI and
317M.J. Pineda et al. / Virology 363 (2007) 310–318EcoRI and cloned into NotI and EcoRI restriction enzyme-
digested pCI-Neo (Promega, Madison WI) to generate pCI-
Neo-SIVMneCL8env. The sequence of the clone was verified
by nucleotide sequencing of both strands.
Preparation of pseudotyped virus particles
Virus stocks were prepared by transient transfection of
HEK293T cells with the Fugene6 reagent (Roche, Indianapolis,
IN) according to the manufacturer's instructions. Cell-free virus
was harvested 2 days post transfection, filtered through 0.22 μm
pore size filter (Steriflip Filters, Millipore, Billerica, MA), and
frozen at −80 °C for long-term storage. HIV-1 envelope
pseudotyped viral stocks were prepared by co-transfection of a
HIV-1 provirus plasmid lacking the envelope gene [either the
clade A Q23Δenv (Long et al., 2002), or the clade B
pLAI3ΔenvGFP3 (Yamashita and Emerman, 2004)] and either
a lentiviral envelope expression plasmid or the vesicular sto-
matitis virus G protein (VSV-G) expression plasmid pMD.G
(Naldini et al., 1996). When high-titer HIV-1 envelope pseudo-
typed virus was needed, virus was concentrated ∼10-fold using
100,000 MWCO Amicon Ultra-15 Centrifugal Filter Devices
from Millipore (Billerica, MA) by centrifugation at 4000 rpm in
Beckman Allegra 6KR Centrifuge at 4 °C for 15 min followed
by two washes using an equal volume of cold PBS prior to
freezing at −80 °C. HIV-1 VLP were generated by transient
transfection of HEK293T cells with a packaging-defective and
envelope-deleted HIV-1 proviral genome (Zufferey et al.,
1997) in the presence and absence (to generate bald VLP) of
pMD.G. HIV-1 Gag p24 concentration was determined by Gag
p24 antigen capture ELISA as per manufacturer instructions
(Beckman-Coulter, Miami, FL). The titer of the virus stocks
were determined using MAGI-CCR5 cells, which express both
CCR5 and CXCR4, as well as CD4, and thus are permissive to
both R5 and X4 HIV-1, as well as SIV (Chackerian et al.,
1997).
Infection assays
For infections, target cells were seeded the day before in 24-
well plates: 4×104 MAGI-CCR5 cells per well, 2×104 sMAGI
(and derivatives) cells per well. MAGI-CCR5 cells, and sMAGI
cells were infected in the presence of DEAEDextran at 20 μg/ml
or 15 μg/ml, respectively. Infectivity was assessed at 2 (MAGI-
CCR5) or 3 (sMAGI) days post-infection. In cases where cells
were infected with pseudotypes of Q23Δenv, cells were fixed
and stained for β-galactosidase expression as in Chackerian et
al. (1995). In cases where cells were infected with pseudotypes
of pLAI3ΔenvGFP3, cells were processed for analysis of GFP
expression by flow cytometry using a Becton Dickenson FACS
Calibur with a High Throughput Sampler: Cells in 24-well plates
were trypsinized (MAGI-CCR5with 0.25% trypsin, sMAGI and
derivatives with 0.05% trypsin), suspended in DMEM complete
and transferred to a 96-well V-bottom plate. Cells were pelleted
by centrifugation at 300×g, then suspended and incubated in
1.2% paraformaldehyde in PBS (USB Corporation, Cleveland,
OH) for 5 min at room temperature. Cells were washed twice inPBS and suspended in a final volume of 75 μl PBS in preparation
for flow cytometry.
RNA interference
Rhesus sMAGI TRIM5α mRNA was reduced using short
interfering RNAs (siRNA) that correspond to siRNA3 and the
control siRNA as described by Stremlau et al. (2004). About
100,000 target cells were seeded into each well of a six-well
plate and transfected with 120 nM siRNA by using 10 μl of
Oligofectamine (Invitrogen, Carlsbad, CA) according to the
manufacturer's instructions. After 24 h, cells were re-plated for
infection by HIV-1 pseudotype virus as described above.
Quantification of reverse transcription intermediates
To minimize DNA contamination in these experiments, we
used replication-competent HIV-1 SF162 that had been
passaged for 12 days in human peripheral blood mononuclear
cells (PBMCs). PBMC cell-free virus was prepared by
centrifugation at 2000 rpm in Beckman Allegra 6KR centrifuge
for 5 min at room temperature. The HIV-1 SF162 virus pre-
paration was aliquotted and stored at −80 °C. As an additional
means to reduce DNA contamination, the virus was incubated
for 30 min at room temperature with 200 U/ml DNaseI
(Invitrogen, Carlsbad, CA) and 10 mM MgCl2.
In preparation for infection, 2×104 sMAGI or sMAGI-
CCR5 cells were plated into each well of a 24-well dish. The
next day, the appropriate control wells were incubated at 37 °C
for 2 h with 50 μM AZT (Sigma, St. Louis, MO) and 50 μM
3TC (NIH AIDS Research and Reference Reagent Program).
The cells were then infected in duplicate, in the presence of
DEAE Dextran as described above, with different MOIs of HIV-
1 SF162. At 4 h post-infection, cells were washed twice in PBS
and then lysed in lysis buffer (50 mM KCl, 10 mM Tris–HCl
(pH 8.3), 2.5 mM MgCl2, 0.1 mg/ml gelatin, 0.45% Nonidet P-
40, and 0.45% Tween 20). Lysates were frozen at −20 °C until
total DNA was extracted using QiAmp DNA Mini-prep kit
according to the manufacturer's instructions (Qiagen, Valencia,
CA). The DNAwas eluted with 100 μl of water. HIV-1 proviral
copies were determined by real time PCR as described in
Rousseau et al. (2004) with 10 μl of template in a final reaction
volume of 50 μl. To control for residual DNA in the virus
preparations after DNaseI treatment, AZT/3TC infections were
performed in the presence of 50 μM AZT and 50 μM 3TC. The
values obtained for the AZT/3TC-treated control were sub-
tracted from the values for untreated infections at each virus
dilution tested.
Fusion assay
Cos7 cells were plated at a density of 5×105 cells per 6 cm
dish. The next day, the Cos7 cells were transiently transfected
with 2 μg of various Env expressing plasmids using Fugene6.
Within 24 h of transfection, Cos7 cells were trypsinized,
counted and plated at a density of 5×104 cells per well of a two
chamber culture slide (Becton-Dickinson, Bedford, MA).
318 M.J. Pineda et al. / Virology 363 (2007) 310–318sMAGI, sMAGI-CCR5, MAGI and MAGI-CCR5 target cells
were added to the Env-expressing Cos7 cells at cell densities of
2×105, 2×105, 5×104 and 5×104 cells/well, respectively.
After 48 h, culture slides were washed twice with cold 1× PBS
and incubated at −20 °C in 1 ml of 1:1 acetone/methanol for
10 min. Acetone/methanol mixture was aspirated and culture
slides were air-dried for 10 min at room temperature. Culture
slides were then rehydrated in cold 1× PBS and stored at 4 °C
until the immunofluorescence assay was performed. Slides were
stained for 1 h at 37 °C in 400 μl of IFA Diluent (1× PBS, 1%
BSA, 5% normal goat serum) containing 1 ng/ml IgG1 b12 to
examine HIV-1 envelope syncytia (IgG1 b12 was a gift of D.
Burton, The Scripps Research Institute, San Diego, CA) or
50 ng/ml SIVIG to examine SIVenvelope syncytia (SIVIG was
a gift of N. Haigwood, SBRI, Seattle, WA). At the end of the
incubation, culture slides were washed twice for 10 min at room
temperature on a nutator with 2 ml of 1× PBS. 400 μl of IFA
diluent containing FITC-conjugated goat anti-human antibody
(ICN, Aurora, OH) was added to each well of the culture slide
and the slides were incubated at 37 °C for 1 h. The stained
culture slides were washed as before and then air-dried at room
temperature for 10 min. Slides were mounted with VectaShield
(Vector Laboratories, Burlingame, CA) and stored in the dark at
4 °C until examined visually by fluorescence microscopy.Acknowledgments
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